| Subject: | FDA Public Health Advisory - Suspended Marketing of NeutroSpec |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Tue, 20 Dec 2005 - 10:00 am |
| FDA issued a public health advisory to inform patients and healthcare providers that Palatin Technologies, the manufacturer of Neutrospec, Technetium 99m Tc fanolesomab, is voluntarily suspending marketing of Neutrospec effective immediately due to serious safety concerns.
This suspension is a follow-up to the safety letter from the Manufacturer that was reviewed in the December 14, 2005 StayAlert.
Neutrospec is an antibody radio-labeled with technetium-99m, indicated for radiologic imaging... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
REFERENCES:
Policies / Forms / Additional Resources:
External Links:
|
|
With over 20 years experience in regulatory compliance, MCN Healthcare brings you the most comprehensive regulatory compliance tool available. StayAlert! is the only comprehensive e-mail notification service available that not only notifies you of the changes in major federal regulations, but also provides the policies, procedures, tools and best practices to help you meet the changing regulation. StayAlert! actively monitors TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others so you don't have to. StayAlert! is the only comprehensive clinical and regulatory service providing organizations in the healthcare arena with practical applications to meet complex mandated federal requirements. |
|
